Nunn A., Dickman S., Nattrass N., Cornwall A., Gruskin S.
Division of Infectious Diseases, Warren Alpert Medical School of Brown University and The Miriam Hospital, Providence, RI, United States; Division of Infectious Diseases, The Miriam Hospital, Providence, RI, United States; Center for Social Science Research, University of Cape Town, Rondebosch, South Africa; Keck School of Medicine, Gould School of Law, Institute for Global Health, University of Southern California, Los Angeles, CA, United States
Nunn, A., Division of Infectious Diseases, Warren Alpert Medical School of Brown University and The Miriam Hospital, Providence, RI, United States; Dickman, S., Division of Infectious Diseases, The Miriam Hospital, Providence, RI, United States; Nattrass, N., Center for Social Science Research, University of Cape Town, Rondebosch, South Africa; Cornwall, A., Division of Infectious Diseases, The Miriam Hospital, Providence, RI, United States; Gruskin, S., Keck School of Medicine, Gould School of Law, Institute for Global Health, University of Southern California, Los Angeles, CA, United States
Brazil and South Africa were among the first countries profoundly impacted by the HIV/AIDS epidemic and had similar rates of HIV infection in the early 1990s. Today, Brazil has less than 1% adult HIV prevalence, implemented treatment and prevention programmes early in the epidemic, and now has exemplary HIV/AIDS programmes. South Africa, by contrast, has HIV prevalence of 18% and was, until recently, infamous for its delayed and inappropriate response to the HIV/AIDS epidemic. This article explores how differing relationships between AIDS movements and governments have impacted the evolving policy responses to the AIDS epidemic in both countries, including through AIDS programme finance, leadership and industrial policy related to production of generic medicines. © 2012 Copyright Taylor and Francis Group, LLC.
generic drug; acquired immune deficiency syndrome; article; Brazil; comparative study; epidemic; health care policy; health program; human; Human immunodeficiency virus infection; priority journal; South Africa; Brazil; Drug Industry; Female; Health Policy; Health Services Accessibility; HIV Infections; Humans; Leadership; Male; Patient Advocacy; South Africa